Sign In / Join

close

Conferences

Our Conferences articles contain the latest coverage of medical advancements from recent academic conferences.

Headlines All Categories Treatment Advances Navigating Your Health Core Education Patient Stories HealthTree Research Conferences Clinical Trials HealthTree Programs HealthTree Press

Recent Articles

Understanding TP53 Mutations in AML and MDS: Expert Insights from ASH 2024

December 27, 2024

The best treatment options for TP53-mutated AML and MDS today are clinical trials. Read expert perspectives from ASH 2024 educational session.

Effects of Eating Fiber, Plant-Based Diet, Keto Diet, and Smoking on Certain Blood Cancers

December 10, 2024

Read research highlights from the ASH 2024 conference how certain lifestyle choices affect blood cancers.

The Best of ASH 2024

December 10, 2024

Discover the board's selection of best abstracts at the 66th annual ASH conference.

Patient Experience and Quality of Life Take Center Stage in MDS Research

December 06, 2024

ASH 2024 first day with news on MDS research in patient quality of life, caregiver burden, and innovative treatment approaches. Read a summary here!

The ASH Warm-Up: Expert Perspectives on Evolving MDS Treatment and Care

December 05, 2024

Review the latest updates in MDS care from a pre-ASH session. Learn about new therapies, clinical trials, and expert insights to guide your treatment decisions.

What is the ASH Conference?

December 02, 2024

The American Society of Hematology's annual conference is a significant event for the blood cancer community, including those involved in MDS research.

EHA 2024: Ivosidenib for High-Risk MDS Patients Updated Results

August 26, 2024

EHA 2024: Ivosidenib for High-Risk MDS

EHA 2024: How Effective is Elritercept for Low-Risk MDS Patients?

August 05, 2024

MDS specialists from Spain shared how elritercept is helping low-risk MDS patients reduce anemia and iron overload symptoms.

ASCO 2024: How Can Palliative Care Help High-Risk MDS Patients?

July 02, 2024

Dr. El-Jawahri shared how palliative care can improve high-risk MDS patients’ quality of life and better prepare them for potential end-of-life care plans.

ASCO 2024: What’s the Right Dose of Azacitidine for Low- and Intermediate-Risk MDS Patients?

June 20, 2024

ASCO 2024: azacitidine for low- and intermediate-risk MDS

Conferences

Recent Articles

Understanding TP53 Mutations in AML and MDS: Expert Insights from ASH 2024

Effects of Eating Fiber, Plant-Based Diet, Keto Diet, and Smoking on Certain Blood Cancers

The Best of ASH 2024

Patient Experience and Quality of Life Take Center Stage in MDS Research

The ASH Warm-Up: Expert Perspectives on Evolving MDS Treatment and Care

What is the ASH Conference?

EHA 2024: Ivosidenib for High-Risk MDS Patients Updated Results

EHA 2024: How Effective is Elritercept for Low-Risk MDS Patients?

ASCO 2024: How Can Palliative Care Help High-Risk MDS Patients?

ASCO 2024: What’s the Right Dose of Azacitidine for Low- and Intermediate-Risk MDS Patients?

Trending Articles

How Blood Clotting and Bleeding Complications Impact Survival of Patients with MDS

Understanding TP53 Mutations in AML and MDS: Expert Insights from ASH 2024

Patient Experience and Quality of Life Take Center Stage in MDS Research

Low-Risk MDS Patients See Limited Benefit from Traditional Anemia Treatment (ESAs)

The ASH Warm-Up: Expert Perspectives on Evolving MDS Treatment and Care

Thanks to our HealthTree Community for Myelodysplastic Syndromes Sponsors:

Follow Us

Education

Community

Cure Hub

Get Involved

About us

Need Help?

Legal Info

Conferences

Recent Articles

Understanding TP53 Mutations in AML and MDS: Expert Insights from ASH 2024

Effects of Eating Fiber, Plant-Based Diet, Keto Diet, and Smoking on Certain Blood Cancers

The Best of ASH 2024

Patient Experience and Quality of Life Take Center Stage in MDS Research

The ASH Warm-Up: Expert Perspectives on Evolving MDS Treatment and Care

What is the ASH Conference?

EHA 2024: Ivosidenib for High-Risk MDS Patients Updated Results

EHA 2024: How Effective is Elritercept for Low-Risk MDS Patients?

ASCO 2024: How Can Palliative Care Help High-Risk MDS Patients?

ASCO 2024: What’s the Right Dose of Azacitidine for Low- and Intermediate-Risk MDS Patients?

Trending Articles

How Blood Clotting and Bleeding Complications Impact Survival of Patients with MDS

Understanding TP53 Mutations in AML and MDS: Expert Insights from ASH 2024

Patient Experience and Quality of Life Take Center Stage in MDS Research

Low-Risk MDS Patients See Limited Benefit from Traditional Anemia Treatment (ESAs)

The ASH Warm-Up: Expert Perspectives on Evolving MDS Treatment and Care

Sign Up for Exclusive Myelodysplastic Syndromes Updates & Resources.

Thanks to our HealthTree Community for Myelodysplastic Syndromes Sponsors:

Follow Us

Education

Community

Cure Hub

Get Involved

About us

Need Help?

Legal Info